Varenicline Prevents LPS-Induced Inflammatory Response via Nicotinic Acetylcholine Receptors in RAW 264.7 Macrophages

• DOI: 10.3389/fmolb.2021.721533
• Publication Date: 2021-10-13T17:47:28Z
• Authors: Elif Baris; Hande Efe; Mukaddes Gumustekin; Mualla Aylin Arici; Metiner Tosun
• Keywords: Varenicline; Methyllycaconitine

The cholinergic anti-inflammatory pathway plays an important role in controlling inflammation. This study investigated the effects of varenicline, α7 nicotinic acetylcholine receptor (α7nAChR) agonist, on inflammatory cytokine levels, cell proliferation, and migration rates a lipopolysaccharide (LPS)-induced inflammation model RAW 264.7 murine macrophage lines. cells were treated with increasing concentrations followed by LPS incubation for 24 h. Prior to receptor-mediated events, varenicline different cytokines chemokines using array. Nicotinic AChR-mediated non-selective nAChR antagonist mecamylamine hydrochloride selective α7nAChR methyllycaconitine citrate. TNFα, IL-1β, IL-6 levels determined ELISA test media h after administration compared those dexamethasone. cellular proliferation monitored drug treatment real-time analysis system. Varenicline decreased LPS-induced including IL-6, IL-1β via α7nAChRs similar level that observed without any involvement. On other hand, rate α7nAChR. Our data suggest inhibits response activating within pathway, reducing migration.